Steven T DeKosky
Overview
Explore the profile of Steven T DeKosky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
306
Citations
23102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zheng D, Cid R, Ortega A, Crocco E, Vaillancourt D, Armstrong M, et al.
Int Psychogeriatr
. 2025 Mar;
37(2):100005.
PMID: 40086908
Objectives: To evaluate the predictive utility of proactive semantic interference (PSI) and failure to recover from proactive semantic interference (frPSI) deficits on the longitudinal everyday functional decline on the Clinical...
2.
Sex-stratified genome-wide meta-analysis identifies novel loci for cognitive decline in older adults
Acharya V, Fan K, Snitz B, Ganguli M, DeKosky S, Lopez O, et al.
Alzheimers Dement
. 2025 Mar;
21(3):e14461.
PMID: 40042063
Introduction: Many complex traits and diseases show sex-specific biases in clinical presentation and prevalence. Methods: To understand sex-specific genetic architecture of cognitive decline across five cognitive domains (attention, memory, executive...
3.
Wei Y, Winterstein A, Schmidt S, Fillingim R, Schmidt S, Daniels M, et al.
J Am Med Dir Assoc
. 2025 Feb;
26(4):105522.
PMID: 40015331
Objectives: Clinical decisions to continue or discontinue long-term opioid therapy (LTOT; ≥3 months) for older cancer survivors remain challenging due to limited evidence on the risks and benefits of this...
4.
Wei Y, Winterstein A, Schmidt S, Fillingim R, Schmidt S, Daniels M, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e70002.
PMID: 39989238
Introduction: Whether prescription opioid exposure, duration, and dose are associated with cognitive function remains inconclusive. Methods: A longitudinal cohort among 3097 older adults with chronic pain and without dementia was...
5.
Asken B, Cid R, Crocco E, Armstrong M, Levy S, Arias F, et al.
J Prev Alzheimers Dis
. 2025 Jan;
12(1):100011.
PMID: 39800468
Background: Mild cognitive impairment (MCI) is a clinical diagnosis representing early symptom changes with preserved functional independence. There are multiple potential etiologies of MCI. While often presumed to be related...
6.
Aksu S, Indahlastari A, OShea A, Marsiske M, Cohen R, Alexander G, et al.
Geroscience
. 2024 Nov;
47(1):1361-1380.
PMID: 39614040
Cognitive aging has become a public health concern as the mean age of the population is ever-increasing. It is a naturalistic and common process of degenerative and compensatory changes that...
7.
Lopez F, OShea A, Huo Z, DeKosky S, Trouard T, Alexander G, et al.
Geroscience
. 2024 Oct;
PMID: 39477865
The goal of the current study was to learn about the role of cerebral mitochondrial function on cognition. Based on established cognitive neuroscience, clinical neuropsychology, and cognitive aging literature, we...
8.
Tang H, Shaaban C, DeKosky S, Smith G, Hu X, Jaffee M, et al.
Alzheimers Res Ther
. 2024 Sep;
16(1):206.
PMID: 39294787
Background: Previous research on the risk of dementia associated with education attainment, smoking status, and alcohol use disorder (AUD) has yielded inconsistent results, indicating potential heterogeneous treatment effects (HTEs) of...
9.
Tang H, Lu Y, Okun M, Donahoo W, Ramirez-Zamora A, Wang F, et al.
Mov Disord
. 2024 Aug;
39(11):1960-1970.
PMID: 39189078
Background: Previous studies have suggested that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may have a disease-modifying effect in the development of Parkinson's disease (PD), but population studies yielded inconsistent results. Objective:...
10.
Wei Y, Winterstein A, Schmidt S, Fillingim R, Daniels M, DeKosky S, et al.
Ann Intern Med
. 2024 Jul;
177(8):1058-1068.
PMID: 39038293
Background: Limited evidence exists on the safety of pharmacokinetic interactions of cytochrome P450 (CYP) 2D6 (CYP2D6)-metabolized opioids with antidepressants among older nursing home (NH) residents. Objective: To investigate the associations...